EFFECT OF SGLT-2 INHIBITORS, GLP-1 RECEPTOR AGONISTS ON CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES, NAFLD, AND CHRONIC KIDNEY DISEASE: A REAL WORLD EVIDENCE

被引：0
|
作者：
Krishnan, Arunkumar
Mukherjee, Diptasree
Althwanay, Aldanah
Woreta, Tinsay A.
Alqahtani, Saleh A.
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1558
引用
收藏
页码：S474 / S475
页数：2
相关论文
共 50 条
  • [31] Comparative effectiveness of GLP-1 receptor agonists versus SGLT2 inhibitors in patients with type 2 diabetes and moderate chronic kidney disease
    Rossing, P.
    Fioretto, P.
    Clark, A.
    Jensen, A. B.
    Nazal, N. Belmar
    Tuttle, K. R.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S356 - S357
  • [32] Cardio-Renal Benefits of GLP-1 Receptor Agonists vs. SGLT-2 Inhibitors in Type 2 Diabetes: Are They Juxtaposed?
    Singh, Awadhesh Kumar
    Shah, Viral N.
    CLINICAL DIABETOLOGY, 2022, 11 (04): : 215 - 221
  • [33] EFFICACY OF GLP-1 RECEPTOR AGONISTS AND SGLT-2 INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES IN LIVER TRANSPLANT RECIPIENTS
    Azhie, Amirhossein
    Gupta, Sarang
    Misra, Shruti
    Chen, Shiyi
    Meerasa, Ameena
    Dash, Satya
    Woo, Minna
    Bhat, Mamatha
    GASTROENTEROLOGY, 2022, 162 (07) : S753 - S753
  • [34] SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease
    Sajja, Aparna P.
    Dey, Amit K.
    Guha, Avirup
    Elnabawi, Youssef
    Joshi, Aditya A.
    Kalra, Ankur
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2019, 24 (05) : 422 - 427
  • [35] The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists
    Serowik, Thomas C.
    Pantalone, Kevin M.
    JOURNAL OF OSTEOPATHIC MEDICINE, 2024, 124 (03): : 127 - 135
  • [36] GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
    Neumiller, Joshua J.
    Alicic, Radica Z.
    Tuttle, Katherine R.
    KIDNEY AND DIALYSIS, 2022, 2 (03): : 386 - 398
  • [37] GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
    Isabel del Olmo-Garcia, Maria
    Francisco Merino-Torres, Juan
    JOURNAL OF DIABETES RESEARCH, 2018, 2018
  • [38] Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
    Edwards, Khary
    Li, Xilong
    Lingvay, Ildiko
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04): : 920 - 930
  • [39] Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk
    Bailey, Clifford J.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (02): : 97 - 99
  • [40] Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
    Lugner, Moa
    Sattar, Naveed
    Miftaraj, Mervete
    Ekelund, Jan
    Franzen, Stefan
    Svensson, Ann-Marie
    Eliasson, Bjoern
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
12345